Form: 8-K

Current report filing

September 14, 2005

8-K: Current report filing

Published on September 14, 2005


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported): September 14, 2005




Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)


Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)


2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (214) 905-5100
--------------



Item 1.01 Entry into a Material Definitive Agreement
-------------------------------------------
Access Pharmaceuticals, Inc. issued a press release on September 14, 2005, a
copy of which is attached as Exhibit 99.1 to this report and incorporated
herein by this reference, in which it announced the status of its 7%
(Subject to Adjustment) Convertible Notes which were due September 13, 2005.


Item 7.01 Regulation FD Disclosure
------------------------

Access Pharmaceuticals, Inc. issued a press release on September 14, 2005, a
copy of which is attached as Exhibit 99.1 to this report and incorporated
herein by this reference, in which it announced the status of its 7%
(Subject to Adjustment) Convertible Notes which were due September 13, 2005.
This information shall not be deemed to be "filed" for the purposes
of Section 18 of the Securities Exchange Act of 1934 and shall not be
deemed to be incorporated by reference in any filing under the Securities
Act of 1933.






2

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.



Access Pharmaceuticals, Inc.
(Registrant)

By: /s/ Stephen B. Thompson
------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer

Dated September 14, 2005

3

EXHIBIT INDEX

Exhibit
Number Description
- ------- ------------
99.1 Press Release, date September 14, 2005

4